← Leaderboards
Mark E McDonnell
Vironika, Llc
$4,736,700
Attributed
$4,736,700
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,736,700 · 4
By mechanism
R44$3,800,000 · 2
R43$936,700 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Analog”
- David Heimbrook · Leidos Biomedical Research, Inc.$196,589,777
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Norman Wolmark · Nsabp Foundation, Inc.$51,982,954
- Robert Turner Schooley · University Of Colorado Denver$48,513,949
- Kenneth A Bloom · University Of Nebraska-Lincoln$46,979,168
- John Hobbs · Suny At Stony Brook$41,239,084
Research focus
AnalogPharmaceutical PreparationsCellsBiochemicalPropertyPharmaceutical ChemistryProgramsMouse ModelIn VivoLeadSmall MoleculeToxic EffectSmall Business Innovation Research GrantCytotoxicityPermeabilityNovel TherapeuticsPlasma ProteinsInfectionEnsureMetabolismBenznidazoleAfricaCostAbsorption
Grant awards (8)
Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle$1,000,000
R44 · FY2025 · AI · contact PI
Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle$1,000,000
R44 · FY2024 · AI · contact PI
Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle$1,050,000
R44 · FY2023 · AI · contact PI
Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle$299,999
R43 · FY2021 · AI · contact PI
Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle$300,000
R43 · FY2020 · AI · contact PI
Development of a Small Molecule Inhibitor for EBV Latent Infection$750,000
R44 · FY2015 · AI · contact PI
Development of a Small Molecule Inhibitor for EBV Latent Infection$91,124
R43 · FY2013 · AI · contact PI
Development of a Small Molecule Inhibitor for EBV Latent Infection$245,577
R43 · FY2012 · AI · contact PI